Likewise, in the phase II clinical trial administering EGFR-CAR T-cell therapy in patients with EGFR-positive relapsed/refractory non-small lung cancer (NSCLC), two patients achieved partial remission and five patients had stable disease for two to eight months with no substantial adverse effect (NCT01869166). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.